Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095707 | 0.99 | LMNA (0.44) | LMNAKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL1094922 | 0.88 | MEN1 (0.52) | LMNAKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL1095845 | 0.86 | SCD (0.57) | LMNAKDM4ESMN1; SMN2SCD | |
| SCHEMBL1601199 | 0.85 | SCD (0.57) | LMNAKDM4ESMN1; SMN2SCD | |
| SCHEMBL1096462 | 0.84 | SMN1; SMN2 (0.52) | LMNAKDM4ESMN1; SMN2KMT2AUSP2 | |
| SCHEMBL1095672 | 0.83 | SMN1; SMN2 (0.53) | LMNAKDM4ESMN1; SMN2KMT2AUSP2 | |
| SCHEMBL1098036 | 0.82 | SCD (0.56) | LMNAKDM4ESMN1; SMN2SCD | |
| SCHEMBL1095840 | 0.82 | HSD17B10 (0.51) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL1096699 | 0.81 | HSD17B10 (0.52) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL3671799 | 0.79 | SCD (0.56) | LMNASMN1; SMN2USP2ALDH1A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4782008-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2006-09-07 | — | — | US | claimed |
| US-8153636-B2 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | disclosed |
| EP-2316825-A1 | Pyridyl derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-7919484-B2 | Combination therapy | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199802-A1 | Pyridyl derivatives and their use as therapeutic agents | PYCR1, PNPO, UQCRC1 | LMNA 163/4885KDM4E 3073/4885SMN1; SMN2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.